Historical development of balsalazide (Colazide®)

Research and Clinical Forums

Volumn 20, Issue 3, 1998, Pages 75-83

  Lennard Jones, J E ^a  

^a ST MARK S HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BALSALAZIDE; MESALAZINE; SALAZOSULFAPYRIDINE; SULFAPYRIDINE;

COLON; CONFERENCE PAPER; DRUG EFFICACY; HUMAN; SIDE EFFECT; ULCERATIVE COLITIS;

EID: 0031798487     PISSN: 01433083     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (27)

1. SVARTZ, N. Salazopyrin, a new sulphanilamide preparation, a) Therapeutic results in rheumatic polyarthritis, b) Therapeutic results in ulcerative colitis, c) Toxic manifestations in treatment with sulphanilamide preparations. Acta Med. Scand., 1942; 110: 577-598.
2. SVARTZ, N. The treatment of ulcerative colitis. Gastroenterologia, 1956; 86: 683-688.
3. MORRISON, L.M. Results of treatment of ulcerative colitis with salicylazosulfapyridine. Gastroenterology, 1952; 21: 133-138.
4. MOERTEL, G.G. and BARGEN, J.A. A critical analysis of the use of salicylazosulfapyridine in chronic ulcerative colitis. Ann. Intern. Med., 1959; 51: 879-889.
5. BARON, J.H., CONNELL, A.M., LENNARD-JONES, J.E. and JONES, F.A. Sulphasalazine and salicylazosulphadimidine in ulcerative colitis. Lancet, 1962; i: 1094-1096.
6. MISIEWICZ, J.J., LENNARD-JONES, J.E., CONNELL, A.M., BARON, J.H. and JONES, F.A. Controlled trial of sulphasalazine in maintenance therapy for ulcerative colitis. Lancet, 1965; 1: 185-188.
7. DICK, A.P., GRAYSON, M.J., CARPENTER, R.G. and PETRIE, A. Controlled trial of sulphasalazine in the treatment of ulcerative colitis. Gut, 1964; 5: 437-442.
8. DISSANAYAKE, A.S. and TRUELOVE, S.C. A controlled therapeutic trial of long-term maintenance treatment of ulcerative colitis with sulphasalazine (Salazopyrin®). Gut, 1973; 14: 923-926.
9. BÖTTIGER, L.E. and MÖLLERBERG, H. Metabolic studies on Azulfidine, Azudimidine and one analogue. Acta Med. Scand., 1959; 165: 241-244.
10. RIIS, P., BINDER, V., KRISTENSEN, M., FOLKENBORG, O., HOLTZ, A. and JARNUM, S. The relapse-preventing effect of methyl-salazosulphapyridine compared to salazosulphapyridine during long-term treatment of ulcerative colitis: a double-blind controlled trial. Scand. J. Gastroenterol., 1979; 14: 257-260.
11. PULLAR, T., HUNTER, J.A. and CAPELL, H.A. Which component of sulphasalazine is active in rheumatoid arthritis? Br. Med. J., 1985; 290: 1535-1538.
12. PEPPERCORN, M.A. and GOLDMAN, P. The role of intestinal bacteria in the metabolism of salicylazosulfapyridine. J. Pharmacol. Exp. Ther., 1972; 181: 555-562.
13. PEPPERCORN, M.A. and GOLDMAN, P. Distribution studies of salicylazosulfapyridine and its metabolites. Gastroenterology, 1973; 64: 240-245.
14. AZAD KAHN, A.K., PIRIS, J. and TRUELOVE, S.C. An experiment to determine the active therapeutic moiety of sulphasalazine. Lancet, 1977; ii: 892-895.
15. VAN HEES, P.A.M., VAN TONGEREN, J.H.M. and VAN LIER, H.J.J. Active therapeutic moiety of sulphasalazine. Lancet, 1978; i: 277.
16. VAN HEES, P.A.M., BAKKER, J.H. and VAN TONGEREN, J.H.M. Effect of sulphapyridine, 5-aminosalicylic acid and placebo in patients with idiopathic proctitis: a study to determine the active therapeutic moiety of sulphasalazine. Gut, 1980; 21: 632-635.
17. CAMPIERI, M., LANFRANCHI, G.A., BAZZOCCHI, G., BRIGNOLA, C., SARTI, F., FRANZIN, G., BATTOCCHIA, A., LABO, G. and DAL MONTE, P.R. Treatment of ulcerative colitis with high-dose 5-aminosalicylic acid enemas. Lancet, 1981; ii: 270-271.
18. CHAN, R.P., POPE, D.J., GILBERT, A.P., SACRA, P.J., BARON, J.H. and LENNARD-JONES, J.E. Studies of two novel sulfasalazine analogs, ipsalazide and balsalazide. Dig. Dis. Sci., 1983; 28: 609-615.
19. GIAFFER, M.H., O'BRIEN, C.J. and HOLDSWORTH, C.D. Clinical tolerance to three 5-aminosalicylic acid releasing preparations in patients with inflammatory bowel disease intolerant or allergic to sulphasalazine. Aliment. Pharmacol. Ther., 1992; 6: 51-59.
20. MCINTYRE, P.B. and LENNARD-JONES, J.E. Reversal with basalazide of infertility caused by sulphasalazine. Br. Med. J., 1984; 288: 1652-1653.
21. IRELAND, A., PRIDDLE, J.D. and JEWELL, D.P., Comparison of 5-aminosalicylic acid and N-acetylaminosalicylic acid uptake by the isolated human colonic epithelial cell. Gut, 1992; 33: 1343-1347.
22. MANSFIELD, J.C., GIAFFER, M.H., CANN, P.A., HOLDSWORTH, C.D., MCKENNA, D.M. and THORNTON, P.C. Is high dose basalazide better than sulphasalazine in initial management of ulcerative colitis. Gut, 1991; 32: A1217.
23. GREEN, J.R.B., SWAN, G.H.J., ROWLINSON, A.E., GIBSON, J.A., BROWN, P., KERR, G.D., SWARBRICK, E.T. and THORNTON, P.C. Sulphasalazine or high dose balsalazide to treat acute relapse in ulcerative colitis? Results of a randomized trial. Gastroenterology, 1993; 104: A709.
24. GREEN, J.R.B., LOBO, A.J., HOLDSWORTH, C.D., LEICESTER, R.J., GIBSON, J.A., KERR, G.D., HODGSON, J.H.F., PARKINS, K.J., TAYLOR, M.D. and THE ABACUS INVESTIGATOR GROUP. Balsalazide is more effective and better tolerated than mesalazine in the treatment of acute ulcerative colitis. Gastroenterology, 1998; 114: 1-10.
25. MCINTYRE, P.B., RODRIGUES, C.A., LENNARD-JONES, J.E., BARRISON, I.G., WALKER, J.G., BARON, J.H. and THORNTON, P.C. Balsalazide in the maintenance treatment of patients with ulcerative colitis, a double-blind comparison study with sulphasalazine. Aliment. Pharmacol. Ther., 1988; 2: 237-243.
26. GIAFFER, M.H., HOLDSWORTH, C.D., LENNARD-JONES, J.E., RODRIGUES, C.A., MCINTYRE, P.B., MANJUNATHA, S., BARON, J.H., BARRISON, I.G., POLSON, R.J., HOARE, A.M., DAVIES, G.S.R. and THORNTON, P.C. Improved maintenance of remission in ulcerative colitis by balsalazide 4 g/day compared with 2 g/day. Aliment. Pharmacol. Ther., 1992; 6: 479-485.
27. GREEN, J.R.B., SWAN, C.H.J., ROWLINSON, A., GIBSON, J.A., BROWN, P., KERR, G.D., SWARBRICK, E.T. and THORNTON, P. Short report: comparison of two doses of basalazide in maintaining ulcerative colitis in remission over 12 months. Aliment. Pharmacol. Ther., 1992; 6: 647-652.